JUL 22, 2015 09:00 AM PDT

WEBINAR: Investigative in vitro Drug Toxicology with Human iPSC-derived Cardiomyocytes

10 45 12679

  • Product Manager, Cellular Dynamics International, Inc., A FUJIFILM Company
      Dr. Anson received his doctorate in Neuroscience from the University of Oregon. His postdoctoral studies at the University of Wisconsin in Molecular Genetics focused on examining structure/function relationships in a variety of K+ channels. He trained under Dr. Craig T. January at the University of Wisconsin Medical School, where he worked as an assistant scientist examining hERG channel physiology and pharmacology in healthy and clinical (Long QT) patients. Dr. Anson has authored over two dozen peer-reviewed manuscripts and book chapters. He began working at Cellular Dynamics International in 2005 as the Director of hERG Screening Services and has been in his current Product Manager role, responsible for numerous iCell® products, since 2009.
    • Scientific Manager, Investigative Toxicology, Safety Assessment, Genentech
        Dr. Brock currently oversees in vitro cardiovascular toxicity assays for Genentech's Safety Assessment Dept. He earned his PhD in Neuroscience from Stanford University, where he discovered and characterized a novel class of selective voltage-gated potassium channel blockers. As a postdoc at the NASA Ames Center for Nanotechnology he developed patented technology for solid-state DNA sequencing. He has previously held positions as Sales Scientist and Senior Sales Scientist at AutoMate Scientific and Axion Biosystems respectively, and has authored papers in subjects ranging from potassium channel pharmacology to stem-cell-based modeling of neurodegenerative diseases.

      DATE: July 22, 2015
      TIME: 9:00AM PT, 12:00PM ET

      Human induced pluripotent stem cells (iPSCs) bring human biology into pre-clinical aspects of drug discovery. iPSC-derived cardiomyocytes have emerged as useful tools for detecting and predicting cardiotoxicity and proarrhythmia. The relevant biology of these cardiomyocytes provides a holistic reagent for testing numerous aspects of structural and functional biology, including on- and off-target toxicities. Syncytial hiPSC-derived cardiomyocytes exhibit highly-regular spontaneous beating with low sample-to-sample variation, which makes them adaptable to real-time functional screening in label-free multiwell platforms and facilitates studies of toxicity mechanisms ranging in time course from minutes to weeks. This webinar brings together speakers from Cellular Dynamics International (CDI) and Genentech to provide an overview of the technology and its implementation, respectively.

      Attendees will learn:

      • The functional human cardiac biology that iPSC-cardiomyocytes bring to the drug discovery arena.

      • Strategies and instrumentation with which iPSC-derived cardiomyocytes are used in hypothesis-driven investigative toxicology studies at Genentech.

      • New functional data on iCell Cardiomyocytes², the newest iteration of iCell Cardiomyocytes from CDI.

      Show Resources
      Loading Comments...